全文获取类型
收费全文 | 186372篇 |
免费 | 14994篇 |
国内免费 | 4835篇 |
专业分类
耳鼻咽喉 | 2052篇 |
儿科学 | 8481篇 |
妇产科学 | 4529篇 |
基础医学 | 19343篇 |
口腔科学 | 3710篇 |
临床医学 | 19486篇 |
内科学 | 28536篇 |
皮肤病学 | 3496篇 |
神经病学 | 15207篇 |
特种医学 | 4187篇 |
外国民族医学 | 6篇 |
外科学 | 18565篇 |
综合类 | 28122篇 |
现状与发展 | 19篇 |
一般理论 | 1篇 |
预防医学 | 12295篇 |
眼科学 | 3147篇 |
药学 | 12722篇 |
126篇 | |
中国医学 | 16169篇 |
肿瘤学 | 6002篇 |
出版年
2024年 | 448篇 |
2023年 | 2960篇 |
2022年 | 6250篇 |
2021年 | 8169篇 |
2020年 | 7784篇 |
2019年 | 6943篇 |
2018年 | 6943篇 |
2017年 | 6864篇 |
2016年 | 7111篇 |
2015年 | 6872篇 |
2014年 | 13551篇 |
2013年 | 13856篇 |
2012年 | 11271篇 |
2011年 | 12866篇 |
2010年 | 10417篇 |
2009年 | 9447篇 |
2008年 | 9111篇 |
2007年 | 9107篇 |
2006年 | 8050篇 |
2005年 | 6749篇 |
2004年 | 5724篇 |
2003年 | 5130篇 |
2002年 | 3693篇 |
2001年 | 3311篇 |
2000年 | 2752篇 |
1999年 | 2424篇 |
1998年 | 1954篇 |
1997年 | 1785篇 |
1996年 | 1699篇 |
1995年 | 1542篇 |
1994年 | 1357篇 |
1993年 | 1182篇 |
1992年 | 1052篇 |
1991年 | 846篇 |
1990年 | 755篇 |
1989年 | 661篇 |
1988年 | 649篇 |
1987年 | 562篇 |
1986年 | 507篇 |
1985年 | 719篇 |
1984年 | 572篇 |
1983年 | 377篇 |
1982年 | 440篇 |
1981年 | 387篇 |
1980年 | 335篇 |
1979年 | 286篇 |
1978年 | 175篇 |
1977年 | 136篇 |
1976年 | 111篇 |
1973年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 265 毫秒
11.
12.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献
13.
14.
《Vaccine》2022,40(16):2370-2378
Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Since PRRSV and Mhp co-infections are very common, an efficient dual vaccine against these pathogens is required for the global swine industry. Compared with traditional vaccines, multi-epitope vaccines have several advantages, they are comparatively easy to produce and construct, are chemically stable, and do not have an infectious potential. In this study, to develop a safe and effective vaccine, B cell and T cell epitopes of PRRSV-GP5, PRRSV-M, Mhp-P46, and Mhp-P65 protein had been screened to construct a recombinant epitope protein rEP-PM that has good hydrophilicity, strong antigenicity, and high surface accessibility, and each epitope is independent and complete. After immunization in mice, rEP-PM could induce the production of high levels of antibodies, and it had good immunoreactivity with anti-rEP-PM, anti-PRRSV, and anti-Mhp antibodies. The anti-rEP-PM antibody specifically recognizes proteins from PRRSV and Mhp. Moreover, rEP-PM induced a Th1-dominant cellular immune response in mice. Our results showed that the rEP-PM protein could be a potential candidate for the development of a safe and effective multi-epitope peptide combined vaccine to control PRRSV and Mhp infections. 相似文献
15.
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素(luteinizing hormone,LH)水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。 相似文献
16.
17.
中国抗癌协会神经内分泌肿瘤专业委员会 《中国癌症杂志》2022,32(6):545-579
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一类起源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤,可发生于全身各处,以肺及胃肠胰NEN(gastroenteropancreatic neuroendocrine neoplasm, GEP-NEN)最常见。国内外研究数据均提示,NEN的发病率在不断上升。美国流行病学调查结果显示,与其他类型肿瘤相比,NEN的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专委会在现有循证医学证据基础上,结合已有国内外指南和共识,制订了首版中国抗癌协会神经内分泌肿瘤诊治指南,为临床工作者提供参考。 相似文献
18.
19.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):399-407
PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney. 相似文献
20.